Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ®
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Alex Kelly has been appointed to the
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced its participation in the following upcoming
Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products
Durham, N.C., September 21, 2020 – Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced that Alec Hayes, Ph.D., has joined Elo Life Systems as Vice President of Technology and Products. In his role, Alec will be responsible for Elo’s
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product DURHAM, N.C. and STAMFORD, Conn., Sept.
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
DURHAM, N.C. and PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, in collaboration with Servier, an independent global
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced its participation in the following upcoming investor
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma PBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim Data Expected from PBCAR0191 No Earlier Than Q4 2020 Expect to Select Clinical Candidate for
Elo Life Systems Announces Strategic Partnership with Dole Food Company with the Goal of Saving the Cavendish Banana
Fusarium wilt TR4 threatens the $25 billion banana industry without a cure or remedy on the horizon DURHAM, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced a strategic partnership with the
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced that the Company will regain full rights and all data it
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic – -PBCAR269A is the First Off-the-Shelf Candidate Produced at In-House Manufacturing Center- DURHAM, N.C., June 08, 2020
CAR T Explainer
What do frozen samurai warriors and magic goggles have to do with treating cancer?
Join Precision BioSciences Chief Science Officer Derek Jantz on a journey into the future of cancer therapies and learn how ARCUS—Precision's genome editing technology—is used to make allogenic, donor-derived CAR T cell therapies with the potential to change the way the world battles cancer.